Dec 3, 2008 - Oscient Pharmaceuticals Corporation today announced that the Company and its licensor, Ethypharm SA, have received notice of a Paragraph IV certification on behalf of Lupin Limited, advising of the submission of an Abbreviated New Drug Application with the U.S. FDA for ANTARA (fenofibrate) capsules, 130 and 43 mg doses.
The details can be read here.
No comments:
Post a Comment